Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6ER5

X-ray structure of Trypanothione Reductase from Leishmania infantum in complex with 2-(diethylamino)ethyl 4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzoate

Summary for 6ER5
Entry DOI10.2210/pdb6er5/pdb
DescriptorTrypanothione reductase, FLAVIN-ADENINE DINUCLEOTIDE, 2-(diethylamino)ethyl 4-((3-(4-nitrophenyl)-3-oxopropyl)amino)benzoate, ... (4 entities in total)
Functional Keywordstrypanothione, trypanothione reductase, leishmania infantum trypanothione reductase inhibitors., oxidoreductase
Biological sourceLeishmania infantum
Total number of polymer chains1
Total formula weight54162.99
Authors
Ilari, A.,Fiorillo, A. (deposition date: 2017-10-17, release date: 2018-10-31, Last modification date: 2024-11-20)
Primary citationTurcano, L.,Torrente, E.,Missineo, A.,Andreini, M.,Gramiccia, M.,Di Muccio, T.,Genovese, I.,Fiorillo, A.,Harper, S.,Bresciani, A.,Colotti, G.,Ilari, A.
Identification and binding mode of a novel Leishmania Trypanothione reductase inhibitor from high throughput screening.
Plos Negl Trop Dis, 12:e0006969-e0006969, 2018
Cited by
PubMed Abstract: Trypanothione reductase (TR) is considered to be one of the best targets to find new drugs against Leishmaniasis. This enzyme is fundamental for parasite survival in the host since it reduces trypanothione, a molecule used by the tryparedoxin/tryparedoxin peroxidase system of Leishmania to neutralize hydrogen peroxide produced by host macrophages during infection. In order to identify new lead compounds against Leishmania we developed and validated a new luminescence-based high-throughput screening (HTS) assay that allowed us to screen a library of 120,000 compounds. We identified a novel chemical class of TR inhibitors, able to kill parasites with an IC50 in the low micromolar range. The X-ray crystal structure of TR in complex with a compound from this class (compound 3) allowed the identification of its binding site in a pocket at the entrance of the NADPH binding site. Since the binding site of compound 3 identified by the X-ray structure is unique, and is not present in human homologs such as glutathione reductase (hGR), it represents a new target for drug discovery efforts.
PubMed: 30475811
DOI: 10.1371/journal.pntd.0006969
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.37 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon